Harmony Biosciences Holdings Inc
Closed
SectorHealthcare
33.81 0.87
Overview
Share price change
24h
Min
33.56
Max
33.85
Income | 10M 32M |
|---|---|
Sales | -28M 215M |
P/E Sector Avg | 14.87 60.149 |
EPS | 0.79 |
Profit margin | 15.084 |
Employees | 293 |
EBITDA | -2.8M 49M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +36.96% upside |
Next Earnings | 4 sie 2026 |
|---|
Market Cap | 172M 2.1B |
|---|---|
Previous open | 32.94 |
Previous close | 33.81 |
Harmony Biosciences Holdings Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Harmony Biosciences Holdings Inc Forecast
Price Target
By TipRanks
36.96% upside
12 Months Forecast
Average 46.25 USD 36.96%
High 72 USD
Low 29 USD
Based on 8 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.